Media stories about Juno Therapeutics (NASDAQ:JUNO) have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Juno Therapeutics earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.7328545563286 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Juno’s $9B deal helps venture capitalist Bob Nelsen land on Midas List; Seattle investors don’t make cut (geekwire.com)
- Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis Report 2018 Featuring Key Players – Novartis, Gilead Sciences and Juno Therapeutics (finanzen.ch)
- Cowen Reiterates “Buy” Rating for Juno Therapeutics (JUNO) (americanbankingnews.com)
- Juno Therapeutics’ (JUNO) Buy Rating Reiterated at Citigroup (americanbankingnews.com)
- CAR T Cell Therapy Market is Expected to Grow at the CAGR of 5.96% During 2017-2025: Credence Research (globenewswire.com)
Shares of JUNO remained flat at $$86.96 during mid-day trading on Friday. The stock had a trading volume of 2 shares, compared to its average volume of 5,484,542. Juno Therapeutics has a 52 week low of $19.62 and a 52 week high of $87.01. The company has a quick ratio of 4.77, a current ratio of 3.61 and a debt-to-equity ratio of 0.01.
In other news, CEO Hans Edgar Bishop sold 270,250 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $46.17, for a total value of $12,477,442.50. Following the completion of the sale, the chief executive officer now directly owns 2,772,679 shares of the company’s stock, valued at $128,014,589.43. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Robert Azelby sold 29,131 shares of Juno Therapeutics stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $68.61, for a total value of $1,998,677.91. Following the sale, the executive vice president now directly owns 73,330 shares of the company’s stock, valued at $5,031,171.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 426,465 shares of company stock valued at $24,946,548. Insiders own 15.08% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3339397/juno-therapeutics-juno-receives-media-sentiment-score-of-0-16.html.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.